Alx Oncology Holdings Inc financial data

Symbol
ALXO on Nasdaq
Industry
Pharmaceutical Preparations
Location
323 Allerton Avenue, South San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 511 % -53.1%
Debt-to-equity 30.5 % +111%
Return On Equity -101 % -93.5%
Return On Assets -77.1 % -69.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 52.7M shares +28%
Common Stock, Shares, Outstanding 52.5M shares +28%
Entity Public Float 161M USD -6.49%
Common Stock, Value, Issued 52K USD +26.8%
Weighted Average Number of Shares Outstanding, Basic 51.8M shares +26.8%
Weighted Average Number of Shares Outstanding, Diluted 51.8M shares +26.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 154M USD +41.4%
General and Administrative Expense 26.7M USD -8.23%
Operating Income (Loss) -181M USD -31%
Net Income (Loss) Attributable to Parent -171M USD -31.5%
Earnings Per Share, Basic -3.63 USD/shares -13.4%
Earnings Per Share, Diluted -3.63 USD/shares -13.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.5M USD -59.2%
Other Assets, Current 315K USD
Assets, Current 169M USD -23.2%
Property, Plant and Equipment, Net 3.32M USD -13.4%
Operating Lease, Right-of-Use Asset 4.44M USD -15.2%
Other Assets, Noncurrent 13.1M USD +20.4%
Assets 215M USD -12.7%
Accounts Payable, Current 8.15M USD +98%
Employee-related Liabilities, Current 3.87M USD +28.4%
Liabilities, Current 38.4M USD +119%
Operating Lease, Liability, Noncurrent 3.95M USD -18.5%
Other Liabilities, Noncurrent 7.08M USD +15.1%
Liabilities 55.3M USD +66.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -73K USD +76.6%
Retained Earnings (Accumulated Deficit) -561M USD -44%
Stockholders' Equity Attributable to Parent 159M USD -25.1%
Liabilities and Equity 215M USD -12.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.9M USD -36.3%
Net Cash Provided by (Used in) Financing Activities 3.09M USD
Net Cash Provided by (Used in) Investing Activities 26.5M USD -37.4%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 52.5M shares +28%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 15.6M USD -59.1%
Deferred Tax Assets, Valuation Allowance 96.3M USD +203%
Operating Lease, Liability 4.85M USD -14.2%
Payments to Acquire Property, Plant, and Equipment 148K USD -78.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -171M USD -32.3%
Lessee, Operating Lease, Liability, to be Paid 6.11M USD -17%
Property, Plant and Equipment, Gross 4.98M USD +7.14%
Operating Lease, Liability, Current 897K USD +12.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.26M USD -26.2%
Deferred Tax Assets, Operating Loss Carryforwards 26.5M USD +62.5%
Unrecognized Tax Benefits 3.12M USD +87.8%
Operating Lease, Payments 313K USD +0.97%
Depreciation, Depletion and Amortization 214K USD +0.47%
Deferred Tax Assets, Net of Valuation Allowance 97.9M USD +192%
Share-based Payment Arrangement, Expense 28M USD +11.5%
Interest Expense 1.66M USD +67.5%